Glaukos (6GJ) Price & Analysis

0 Followers

6GJ Stock Chart & Stats

€102.00

€2.00(1.36%)

At close: Jan 08 4:00 PM EST

€102.00

€2.00(1.36%)

Day’s Range― - ―

52-Week Range€63.50 - €139.00

Previous CloseN/A

Volume0.00

Average Volume (3M)19.00

Market Cap

€8.05B

Enterprise Value€6.07K

Total Cash (Recent Filing)€276.69M

Total Debt (Recent Filing)€103.06M

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Jul 29, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.28

Shares Outstanding58,733,910

10 Day Avg. Volume0

30 Day Avg. Volume19

Financial Highlights & Ratios

PEG Ratio-1.87

Price to Book (P/B)9.84

Price to Sales (P/S)12.73

P/FCF Ratio-119.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€142.48

Price Target Upside39.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-0.45

Revenue Forecast (FY)€550.47M

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue & Raised GuidanceSustained double‑digit top‑line growth and a formal guidance raise reflect durable commercial adoption of core glaucoma offerings (notably iDose TR) and expanding procedure volumes. This supports multi‑quarter revenue visibility and underpins reinvestment for market expansion.

High & Improving Gross MarginsExceptionally high gross margins indicate scalable product economics for implantable devices and consumables. Durable margin expansion provides room for marketing and R&D spend while enabling operating‑leverage as sales scale, supporting longer‑term pathway to profitability.

Conservative Balance Sheet / Low LeverageAmple cash and low leverage reduce financial risk while supporting continued commercialization and clinical programs without immediate refinancing pressure. A conservative capital structure lengthens runway for product launches and regulatory timelines.

Bears Say

Persistent Negative Cash FlowContinued negative operating and free cash flow means the business remains dependent on external liquidity to fund growth and launches. Even with improved burn, sustained losses can erode runway and force financing choices that divert resources from commercialization.

Rising Operating Expenses To Fund LaunchesPlanned opex increases to support Epioxa and other launches will pressure near‑term margins and delay break‑even risk despite strong gross margins. Sustained elevated SG&A/R&D spend requires continued revenue execution to justify the investment and achieve leverage.

Payer/Access & Channel Transition FrictionAccess complexity and temporary reimbursement coding create elongated patient access cycles and claim adjudication risk. Structural shifts to specialty pharmacy and new channel workflows can slow adoption, increase working capital needs, and complicate predictable revenue realization.

Glaukos News

Glaukos price target raised to $175 from $170 at Stifel

Stifel raised the firm’s price target on Glaukos (GKOS) to $175 from $170 and keeps a Buy rating...

4d ago

GKOS

Glaukos price target raised to $180 from $160 at Truist

Truist raised the firm’s price target on Glaukos (GKOS) to $180 from $160 and keeps a Buy rating...

5d ago

GKOS

Glaukos price target raised to $164 from $162 at BTIG

BTIG raised the firm’s price target on Glaukos (GKOS) to $164 from $162 and keeps a Buy rating...

8d ago

GKOS

Glaukos price target raised to $175 from $162 at Citi

Citi raised the firm’s price target on Glaukos (GKOS) to $175 from $162 and keeps a Buy rating...

13d ago

GKOS

Okta upgraded, Datadog downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

15d ago

Glaukos initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Glaukos (GKOS) with a Buy rating and $168 price target Glaukos pioneered and...

15d ago

GKOS

Glaukos completes patient enrollment in Phase 2 study of GLK-321

Glaukos (GKOS) announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment...

26d ago

GKOS

Glaukos: Favorable iDose Reimbursement Outlook and Epioxa Launch Drive Attractive Risk-Reward, Supporting Buy Rating

William Blair analyst Steven Lichtman has maintained their bullish stance on GKOS stock, giving a Buy rating on...

13d ago

GKOS

Glaukos price target raised to $150 from $136 at Needham

Needham raised the firm’s price target on Glaukos (GKOS) to $150 from $136 and keeps a Buy rating...

1M ago

GKOS

Glaukos price target raised to $162 from $140 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $162 from $140 and keeps...

1M ago

GKOS

Glaukos: Buy Rating Reiterated on Robust Pipeline and Multi-Product Growth Drivers; $162 Price Target Unchanged

Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Glaukos, retaining the price target of $162.00. Ryan...

1M ago

GKOS

Analyst Reiterates Buy on Glaukos, Maintains $136 Price Target Amid Stable LCD Outlook and Long-Term Growth Potential

Needham analyst David Saxon has maintained their bullish stance on GKOS stock, giving a Buy rating yesterday. David...

1M ago

GKOS

Glaukos Shareholders Reinforce Board, Pay and Auditor Support

Glaukos ( ($GKOS) ) has provided an announcement. At its annual meeting of stockholders held on May 28,...

2M ago

GKOS

Analyst Reiterates Buy on Glaukos, Citing Long-Term iDose Opportunity and Upcoming Epioxa-Driven Growth

William Blair analyst Steven Lichtman has maintained their bullish stance on GKOS stock, giving a Buy rating on...

2M ago

GKOS

6GJ FAQ

What was Glaukos Corp.’s price range in the past 12 months?

Glaukos Corp. lowest stock price was €63.50 and its highest was €139.00 in the past 12 months.

What is Glaukos Corp.’s market cap?

Glaukos Corp.’s market cap is €8.05B.

When is Glaukos Corp.’s upcoming earnings report date?

Glaukos Corp.’s upcoming earnings report date is Jul 29, 2026 which is in 8 days.

How were Glaukos Corp.’s earnings last quarter?

Glaukos Corp. released its earnings results on Apr 29, 2026. The company reported -€0.157 earnings per share for the quarter, beating the consensus estimate of -€0.246 by €0.088.

Is Glaukos Corp. overvalued?

According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Glaukos Corp. pay dividends?

Glaukos Corp. does not currently pay dividends.

What is Glaukos Corp.’s EPS estimate?

Glaukos Corp.’s EPS estimate is -0.19.

How many shares outstanding does Glaukos Corp. have?

Glaukos Corp. has 58,733,910 shares outstanding.

What happened to Glaukos Corp.’s price movement after its last earnings report?

Glaukos Corp. reported an EPS of -€0.157 in its last earnings report, beating expectations of -€0.246. Following the earnings report the stock price went up 17.822%.

Which hedge fund is a major shareholder of Glaukos Corp.?

Currently, no hedge funds are holding shares in DE:6GJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Glaukos Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-7.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Glaukos Corp.

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Glaukos (6GJ) Earnings & Revenues

Historic Earnings Reports

6GJ Stock 12 Month Forecast

Average Price Target

€142.48

▲(39.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"€67","158":"€158","89.75":"€89.8","112.5":"€112.5","135.25":"€135.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157.3388064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€157.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.47903024000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€142.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.62641824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€120.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,89.75,112.5,135.25,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,124.71836972307692,127.43673944615385,130.15510916923077,132.8734788923077,135.5918486153846,138.31021833846154,141.02858806153847,143.7469577846154,146.4653275076923,149.18369723076924,151.90206695384614,154.62043667692308,{"y":157.3388064,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,123.57531001846154,125.15062003692307,126.72593005538462,128.30124007384615,129.8765500923077,131.45186011076925,133.02717012923077,134.60248014769232,136.17779016615387,137.7531001846154,139.32841020307694,140.90372022153846,{"y":142.47903024000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,121.89433986461539,121.78867972923076,121.68301959384615,121.57735945846154,121.47169932307692,121.36603918769231,121.2603790523077,121.15471891692309,121.04905878153846,120.94339864615385,120.83773851076924,120.73207837538462,{"y":120.62641824,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >